bromfenac
Sensory organs (S01)Sensory organs (S01) compound in Zhongshan Ophthalmic Center's portfolio. Mechanism: Cyclooxygenase inhibitor.
- Mechanism
- Cyclooxygenase inhibitor
pharma · Pterygium · Open Angle Glaucoma
Zhongshan Ophthalmic Center
Zhongshan Ophthalmic Center, Sun Yat-sen University
Zhongshan Ophthalmic Center drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Guangzhou, CN HQ
85 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Guangzhou, CN
- Employees
- 85
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Zhongshan Ophthalmic Center pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zhongshan Ophthalmic Center drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Zhongshan Ophthalmic Center in public FDA and regional records.
-
Development asset linked to Zhongshan Ophthalmic Center in public FDA and regional records.
-
Development asset linked to Zhongshan Ophthalmic Center in public FDA and regional records.